Enhanced effectiveness of last generation antiblastic compounds vs. cisplatin on malignant pleural mesothelioma cell lines

Author： de Cupis A.   Semino C.   Pirani P.   Loprevite M.   Ardizzoni A.   Favoni R.E.  

Publisher： Elsevier

ISSN： 0014-2999

Source： European Journal of Pharmacology, Vol.473, Iss.2, 2003-07, pp. : 83-95

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pemetrexed/cisplatin worth it in malignant pleural mesothelioma

By  

Inpharma, Vol. 1, Iss. 1627, 2008-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Raltitrexed + cisplatin beneficial for malignant pleural mesothelioma

By  

Inpharma, Vol. 1, Iss. 1512, 2005-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Pemetrexed + cisplatin: first-line for malignant pleural mesothelioma

By  

Inpharma, Vol. 1, Iss. 1404, 2003-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

JQ1, a BET Inhibitor, Synergizes with Cisplatin and Induces Apoptosis in Highly Chemoresistant Malignant Pleural Mesothelioma Cells

By  

Current Cancer Drug Targets, Vol. 18, Iss. 8, 2018-10 ,pp. : 816-828

Bentham Science Publishers

Access to resources Recommend Favorite

Current chemotherapeutic treatment of malignant pleural mesothelioma

By Nowak Anna K   Byrne Michael J   Millward Michael J   Alvarez John M   Robinson Bruce WS  

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 12, 2004-12 ,pp. : 2441-2449

Informa Healthcare

Access to resources Recommend Favorite